DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

Insulin-like Growth Factor-Dependent Proliferation and Survival of Triple-Negative Breast Cancer Cells: Implications for Therapy

(2015) Zoë Davison et al.   NEOPLASIA

Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody

(2013) H. Song et al.   MOLECULAR CANCER THERAPEUTICS

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

(2012) F. Andre et al.   ANNALS OF ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination

(2011) Michele Tavecchio et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells

(2011) Zhiyong Mao et al.   CELL CYCLE

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

(2011) B Weigelt et al.   ONCOGENE

Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer

(2011) Fadhel S. Shaheen et al.   PLoS One

The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway

(2010) Michael R. Lieber   Annual Review of Biochemistry

Regulation of Homologous Recombination in Eukaryotes

(2010) Wolf-Dietrich Heyer et al.   Annual Review of Genetics

A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation

(2010) Tracey A. Dobbs et al.   DNA REPAIR

Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery

(2009) Jessica Kao et al.   PLoS One

DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia

(2008) E. Willmore et al.   CLINICAL CANCER RESEARCH